Abstract: A method for controlling a vehicle includes: determining an accelerator position sensor/brake pedal position sensor (APS/BPS) command value based on a state variable and a reward variable including a prediction value for a future velocity of the vehicle predicted based on a past APS/BPS command value of the vehicle; and learning for a reward value according to the reward variable to satisfy a predetermined goal based on a change that the determined APS/BPS command value causes to at least one state variable under given environment information.

Abstract: Disclosed is a lighting control system for directing a show. The system includes at least: a master device; and a plurality of slave devices that receive lighting control signals from the master device. The light control signals correspond to seats of a plurality of audiences in an auditorium. The plurality of slave devices receive position information indicating specific positions at which the plurality of slave devices emit a light, light-emitting status information including preset information to classify the plurality of slave devices into a plurality of groups, and group identification number information. The plurality of slave devices are grouped in accordance with received information. The master device controls the grouped plurality of slave devices to emit a light per group basis by broadcasting the lighting control signals including group light-emitting pattern information for each of the plurality of groups of the plurality of slave devices.

Abstract: A cylindrical secondary battery, a battery pack, and a vehicle are provided. The cylindrical secondary battery includes an electrode assembly having a first electrode tab at a first end of the electrode assembly a battery can configured to accommodate the electrode assembly through an opening portion formed at one side of the battery can, a current collecting plate including three or more tab coupling portions electrically connected to the first electrode tab, and a can coupling portion extending from ends of the tab coupling portions toward the opening portion of the battery can and having a continuous outer peripheral surface electrically connected to an inner surface of the battery can, and a top cap configured to cover the opening portion of the battery can.

Abstract: An optical device is disclosed herein. In some embodiments, an optical device includes a first outer substrate, a second outer substrate, a liquid crystal element positioned between the first outer substrate and the second outer substrate, a first intermediate layer between the first outer substrate and the liquid crystal element, and a second intermediate layer between the second outer substrate and the liquid crystal element, wherein a sum of total thicknesses of the first and second intermediate layers is 800 ?m or more, and wherein the liquid crystal element includes a first base layer, a second base layer, a liquid crystal layer between the first base layer and the second base layer, a pressure-sensitive adhesive layer between the first base layer and the liquid crystal layer, and a spacer to maintain a gap between the first and second base layers.

Abstract: A surface-treated inorganic nanoparticle including an inorganic nanoparticle, a first dispersant connected to the inorganic nanoparticle, and a second dispersant connected to the inorganic nanoparticle, wherein a molecular weight (MW) of the first dispersant is different from a molecular weight (MW) of the second dispersant.

Abstract: A lens module is provided. The lens module includes at least one refractive index distribution lens; and a lens barrel configured to accommodate the at least one refractive index distribution lens, wherein the at least one refractive index distribution lens is composed of a single layer, and includes a plastic material.

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

Abstract: The present invention relates to a plasma radical solution and a method for preparing the same, and more particularly, to a plasma radical solution and a method for preparing the same capable of being used in various bio-fields such as sterilization, antibacterial, wound healing, acne relief, atopy treatment, psoriasis treatment, dermatitis treatment, viral skin disease treatment, skin soothing and muscle regeneration by preparing a plasma radical solution containing radicals generated through plasma.

Abstract: A transmittance-variable device is provided in the present application. The present application provides a transmittance-variable device, which can be applied to various applications without causing problems such as a crosstalk phenomenon, a rainbow phenomenon or a mirroring phenomenon, while having excellent transmittance-variable characteristics.

Abstract: A lens is provided. The lens includes a lens unit, and a serrated layer disposed on at least a portion of a surface of the lens unit, wherein the serrated layer includes a plurality of particles dispersed therein that are injected into the serrated layer. The serrated layer includes a plurality of conical structures having different sizes, accordingly, a refractive index on the surface of the serrated layer may gradually change.

Abstract: A coating composition, a method for manufacturing a substrate using the same, and an optical device are provided. The method for manufacturing the substrate provides the substrate having excellent performance, as the substrate has fixed spacers on its surface by using a single layer in which nanoparticles and spacers are dispersed in an alignment film to reduce processes and cost. The optical device may be manufactured by such method.

Abstract: A transmittance-variable device is provided in the present application. The present application provides a transmittance-variable device, which can be applied to various applications without causing problems such as a crosstalk phenomenon, a rainbow phenomenon or a mirroring phenomenon, while having excellent transmittance-variable characteristics.

Abstract: A light modulation element that can vary between a bright transparent mode and a dark scattering mode is provided. The light modulation element has a first light modulation layer and a second light modulation layer comprising nematic liquid crystals and a dichroic dye in a scattering mode when a voltage is applied. The first light modulation layer and the second light modulation layer are disposed to overlap each other. The light modulation element has an improved contrast ratio and haze-variable characteristics, without precipitation of dichroic dyes and an increase in power consumption.

Abstract: A pharmaceutical composition that is useful preventing or treating cancer with a KRAS mutation and activated RON is disclosed. The pharmaceutical composition may be utilized as an anticancer drug that exhibits an excellent cell death-inducing ability on cancer cells with KRAS G13 mutation or KRAS G12 mutation and a RON mutation or tyrosine-phosphorylated RON (pTyr-RON).

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

Abstract: A light modulation device is disclosed herein. In some embodiments, a light modulation device includes a first polymer film substrate, a second polymer film substrate, an active liquid crystal layer disposed between the first and second polymer film substrates, a reflective layer, wherein the active liquid crystal layer is capable of switching between a first orientation state and a second orientation state different from the first orientation state upon application of a voltage, each of the polymer film substrates has an in-plane retardation of 4,000 nm or more for light having a wavelength of 550 nm, a ratio of an elongation (E1) in a first direction to an elongation (E2) in a second direction perpendicular to the first direction of 3 or more, and wherein an angle formed by the first directions of the first and second polymer film substrates is in a range of 0 degrees to 10 degrees.

Abstract: The present disclosure relates to a dispersant containing a specific compound having a fluorene skeleton, and a composition using the same.

Abstract: A light modulation device is disclosed herein. In some embodiments, a light modulation device includes a first polymer film substrate, a second polymer film substrate, an active liquid crystal layer disposed between the first and second polymer film substrates, wherein the active liquid crystal layer is capable of switching between a first orientation state and a second orientation state different from the first orientation state under an applied voltage, the first and second polymer film substrates have an in-plane retardation of 4,000 nm or more for light having a wavelength of 550 nm, a ratio of an elongation (E1) in a first direction to an elongation (E2) in a second direction perpendicular to the first direction of 3 or more, and wherein an angle formed by the first directions of the first and second polymer film substrates is in a range of 0 degrees to 10 degrees.

Abstract: An injection-molded product or an eyewear is provided. The injection-molded product or the eyewear may be an optically compensated injection-molded product, which may resolve optical defects such as a rainbow phenomenon occurring in the injection-molded product or the eyewear. The injection-molded product may include an injection-molded body and a retardation film disposed on at least one side of the injection-molded body. The retardation film has an in-plane phase difference of 1,000 nm or more for light having a wavelength of 550 nm, and wherein an angle formed by a slow axis of the retardation film and an injection direction of the injection-molded body is in a range from 0 degree to 80 degrees.

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.